Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy
Standard
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy : Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. / Spanjaart, Anne Mea; Ljungman, Per; Tridello, Gloria; Schwartz, Juana; Martinez-Cibrián, Nuria; Barba, Pere; Kwon, Mi; Lopez-Corral, Lucia; Martinez-Lopez, Joaquin; Ferra, Christelle; Di Blasi, Roberta; Ghesquieres, Hervé; Mutsaers, Pim; Calkoen, Friso; Jak, Margot; van Doesum, Jaap; Vermaat, Joost S P; van der Poel, Marjolein; Maertens, Johan; Gambella, Massimiliano; Metafuni, Elisabetta; Ciceri, Fabio; Saccardi, Riccardo; Nicholson, Emma; Tholouli, Eleni; Matthew, Collin; Potter, Victoria; Bloor, Adrian; Besley, Caroline; Roddie, Claire; Wilson, Keith; Nagler, Arnon; Campos, Antonio; Petersen, Soeren Lykke; Folber, Frantisek; Bader, Peter; Finke, Jurgen; Kroger, Nicolaus; Knelange, Nina; de La Camara, Rafael; Kersten, Marie José; Mielke, Stephan.
In: LEUKEMIA, Vol. 38, No. 9, 09.2024, p. 1985-1991.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy
T2 - Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
AU - Spanjaart, Anne Mea
AU - Ljungman, Per
AU - Tridello, Gloria
AU - Schwartz, Juana
AU - Martinez-Cibrián, Nuria
AU - Barba, Pere
AU - Kwon, Mi
AU - Lopez-Corral, Lucia
AU - Martinez-Lopez, Joaquin
AU - Ferra, Christelle
AU - Di Blasi, Roberta
AU - Ghesquieres, Hervé
AU - Mutsaers, Pim
AU - Calkoen, Friso
AU - Jak, Margot
AU - van Doesum, Jaap
AU - Vermaat, Joost S P
AU - van der Poel, Marjolein
AU - Maertens, Johan
AU - Gambella, Massimiliano
AU - Metafuni, Elisabetta
AU - Ciceri, Fabio
AU - Saccardi, Riccardo
AU - Nicholson, Emma
AU - Tholouli, Eleni
AU - Matthew, Collin
AU - Potter, Victoria
AU - Bloor, Adrian
AU - Besley, Caroline
AU - Roddie, Claire
AU - Wilson, Keith
AU - Nagler, Arnon
AU - Campos, Antonio
AU - Petersen, Soeren Lykke
AU - Folber, Frantisek
AU - Bader, Peter
AU - Finke, Jurgen
AU - Kroger, Nicolaus
AU - Knelange, Nina
AU - de La Camara, Rafael
AU - Kersten, Marie José
AU - Mielke, Stephan
N1 - © 2024. The Author(s).
PY - 2024/9
Y1 - 2024/9
N2 - COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
AB - COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
U2 - 10.1038/s41375-024-02336-1
DO - 10.1038/s41375-024-02336-1
M3 - SCORING: Journal article
C2 - 39043963
VL - 38
SP - 1985
EP - 1991
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 9
ER -
